Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer

• Status: Completed
• Trial end date: 2017-10-04
• Target enrollment: 0
• Participant gender: Male

Summary

Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. In this real-life, non-interventional trial, any cardiovascular events occurring during degarelix therapy will be documented.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ferring Pharmaceuticals

Criteria

Inclusion Criteria:

• Patients with prostate cancer and a history of cardiovascular disease, prescribed degarelix for the treatment of their prostate cancer

Exclusion Criteria:

• Patients who have received a form of androgen deprivation therapy for their prostate cancer, during the 12 months preceding this study are excluded

• Planned intermittent or short-term (< 12 months) degarelix treatment

• Planned addition of, or switch to another form of androgen deprivation therapy during the study